Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 10/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 10/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | HTR1E | P28566 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1079856 | 0.93 | PTGES (0.45) | PTGESPTGS2MEN1LMNAHTR1E | |
| SCHEMBL1079129 | 0.89 | PTGES (0.60) | PTGESPTGS2MEN1LMNAHTR1E | |
| SCHEMBL1193765 | 0.87 | PTGES (0.55) | PTGESPTGS2MEN1LMNAHTR1E | |
| SCHEMBL12872141 | 0.87 | PTGES (0.50) | PTGESPTGS2MEN1LMNAHTR1E | |
| SCHEMBL1079858 | 0.87 | PTGES (0.50) | PTGESPTGS2MEN1LMNAHTR1E | |
| Bicarbonate SCHEMBL1080702 | 0.86 | PTGES (0.48) | PTGESPTGS2MEN1LMNAHTR1E | |
| SCHEMBL12871669 | 0.86 | PTGES (0.46) | PTGESPTGS2MEN1LMNAHTR1E | |
| SCHEMBL1178602 | 0.86 | PTGES (0.47) | PTGESPTGS2MEN1LMNAHTR1E | |
| SCHEMBL1177604 | 0.86 | HTR1E (0.44) | PTGESPTGS2MEN1LMNAHTR1E | |
| SCHEMBL1178961 | 0.85 | PTGES (0.46) | PTGESPTGS2MEN1LMNAHTR1E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2268625-B1 | OXO-HETEROCYCLIC SUBSTITUTED CARBOXYLIC ACID DERIVATES AND THE USE THEREOF | Bayer Pharma AG (DE) | 2012-05-16 | — | — | EP | disclosed |